SMA
REGN icon

Seven Mile Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

Seven Mile Advisory’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$209K Sell
270
-58
-18% -$44.4K 0.15% 161
2025
Q4 		$253K Buy
+328
New +$223K 0.04% 203

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Seven Mile Advisory's REGN Position: Q1 2026 in Review

Seven Mile Advisory reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q1 2026, selling an estimated $44.4K and leaving 270 shares worth $209K. The position accounts for 0.15% of the portfolio, ranked #161.

Seven Mile Advisory first reported a position in REGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $253K in Q4 2025. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Seven Mile Advisory held 270 shares of Regeneron Pharmaceuticals worth $209K as of Q1 2026.
  • Seven Mile Advisory sold 58 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $44.4K.
  • Regeneron Pharmaceuticals made up 0.15% of Seven Mile Advisory's portfolio in Q1 2026, its #161 holding.
  • Seven Mile Advisory first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Seven Mile Advisory's Regeneron Pharmaceuticals position peaked at $253K in Q4 2025.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Seven Mile Advisory's 13F filing for Q1 2026, filed 14 Apr 2026.